Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of Oncolytic Adenovirus Gene Therapy in Metastatic Pancreatic Cancer
NCT03281382Phase 1Completed
- Sponsor
- Henry Ford Health
- Start
- Jul 2017
- Primary completion
- May 2019
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ad5-yCD/mutTKSR39rep-hIL12 in pancreatic adenocarcinoma (PDAC) (3 cohorts), sponsored by Henry Ford Health. Primary endpoint: Toxicity of the gene therapy at 21 days. Started Jul 2017; status: completed.
02
Drugs
Ad5-yCD/mutTKSR39rep-hIL12
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03281382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03281382.